Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | XDH | P47989 | 2/20 | 0.44 |
| ▸ | TRPM2 | O94759 | 1/20 | 0.41 |
| ▸ | DHODH | Q02127 | 1/20 | 0.41 |
| ▸ | FPR2 | P25090 | 1/20 | 0.41 |
| ▸ | GPR119 | Q8TDV5 | 5/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | PPARG | P37231 | 2/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.37 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.37 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.37 |
| ▸ | BRAF | P15056 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25786862 | 0.92 | SMN1; SMN2 (0.44) | SMN1; SMN2XDHTRPM2DHODHMEN1 | |
| SCHEMBL20553653 | 0.90 | YAP1 (0.46) | SMN1; SMN2NPSR1MEN1KMT2AMAPT | |
| SCHEMBL20552924 | 0.83 | KMT2A (0.43) | XDHTRPM2DHODHFPR2GPR119 | |
| SCHEMBL20552657 | 0.82 | JAK1 (0.43) | DHODHFPR2GPR119MAPT | |
| SCHEMBL20552900 | 0.81 | ABL1 (0.38) | DHODHMEN1KMT2AMAPTHTT | |
| SCHEMBL20551922 | 0.80 | TRPM2 (0.41) | TRPM2DHODHFPR2NPSR1MEN1 | |
| SCHEMBL20551791 | 0.78 | RAB9A (0.45) | SMN1; SMN2TRPM2DHODHFPR2NPSR1 | |
| SCHEMBL20552417 | 0.78 | MAPT (0.55) | SMN1; SMN2NPSR1MEN1KMT2AMAPT | |
| SCHEMBL21765173 | 0.78 | MAPK14 (0.43) | DHODHFPR2NPSR1MAPTPPARG | |
| SCHEMBL20551966 | 0.77 | YAP1 (0.49) | DHODHMEN1KMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230192607-A1 | TRANSCRIPTIONAL ENHANCED ASSOCIATE DOMAIN (TEAD) TRANSCRIPTION FACTOR INHIBITORS AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-06-22 | — | — | US | disclosed |
| US-11186554-B2 | Non-fused tricyclic compounds | VIVACE THERAPEUTICS, INC. (US) | 2021-11-30 | — | — | US | disclosed |
| US-11186554-B2 | Non-fused tricyclic compounds | VIVACE THERAPEUTICS, INC. (US) | 2021-11-30 | — | — | US | disclosed |
| CN-111132673-A | Non-fused tricyclic compounds | 维瓦斯治疗公司 | 2020-05-08 | — | — | CN | disclosed |
| EP-3618818-A1 | NON-FUSED TRICYCLIC COMPOUNDS | Vivace Therapeutics, Inc. (US) | 2020-03-11 | — | — | EP | disclosed |
| US-20200062721-A1 | NON-FUSED TRICYCLIC COMPOUNDS | VIVACE THERAPEUTICS, INC. | 2020-02-27 | — | — | US | disclosed |
| US-20200062721-A1 | NON-FUSED TRICYCLIC COMPOUNDS | VIVACE THERAPEUTICS, INC. | 2020-02-27 | — | — | US | disclosed |
| WO-2018204532-A1 | NON-FUSED TRICYCLIC COMPOUNDS | VIVACE THERAPEUTICS, INC. (US) | 2018-11-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200062721-A1 | NON-FUSED TRICYCLIC COMPOUNDS | YAP1, MYC, TEAD2 | SMN1; SMN2 3160/4885XDH 2391/4885TRPM2 4106/4885 |
| US-11186554-B2 | Non-fused tricyclic compounds | YAP1, MYC, TEAD2 | SMN1; SMN2 3160/4885XDH 2391/4885TRPM2 4106/4885 |
| US-20230192607-A1 | TRANSCRIPTIONAL ENHANCED ASSOCIATE DOMAIN (TEAD) TRANSCRIPTION FACTOR INHIBITORS AND USES THEREOF | TEAD1, TEAD4, TEAD2 | SMN1; SMN2 3035/4885XDH 1387/4885TRPM2 3235/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.